Search results for "hiv-1"

showing 10 items of 177 documents

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct

Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe

2014

Background: One out of ten newly diagnosed patients in Europe was infected with a virus carrying a drug resistant mutation. We analysed the patterns over time for transmitted drug resistance mutations (TDRM) using data from the European Spread program.Methods: Clinical, epidemiological and virological data from 4317 patients newly diagnosed with HIV-1 infection between 2002 and 2007 were analysed. Patients were enrolled using a pre-defined sampling strategy.Results: The overall prevalence of TDRM in this period was 8.9% (95% CI: 8.1-9.8). Interestingly, significant changes over time in TDRM caused by the different drug classes were found. Whereas nucleoside resistance mutations remained con…

Malevirus strainResistanceHIV InfectionsDrug resistanceTHERAPYNucleoside Reverse Transcriptase InhibitorANTIRETROVIRAL DRUG-RESISTANCE0302 clinical medicineMedical microbiologyGenotypeMedicine and Health SciencesPrevalenceHIV Infection030212 general & internal medicineUNITED-KINGDOMPhylogeny0303 health sciencesCommunicable diseaseTransmission (medicine)adultvirus mutationUPDATED RECOMMENDATIONSvirus transmission3. Good healthEuropeInfectious Diseasesfemalerisk factorvirus resistanceFemaleNAIVE PATIENTSSOCIETY-USA PANELResearch ArticleHumanAdultmedicine.medical_specialtyGenotypeAnti-HIV AgentsVirusArticle03 medical and health sciencesSDG 3 - Good Health and Well-beingmaleMOLECULAR EPIDEMIOLOGYDrug Resistance Viralmedicineproteinase inhibitorHumansTransmissioncontrolled studyhumanmolecular phylogeny030304 developmental biologynonhumanMUTATIONSbusiness.industryAnti-HIV Agentnucleotide sequencenonnucleoside reverse transcriptase inhibitorHuman immunodeficiency virus 1 infectionVirologymajor clinical studyunindexed sequenceParasitology3121 General medicine internal medicine and other clinical medicineMutationHIV-1business
researchProduct

Role of individual's T cell immunome in controlling HIV-1 progression

2014

Viral and host factors can influence HIV-1 progression, among them human leucocyte antigen (HLA) has shown the strongest effect. However, studies on the functional contribution of HLA in controlling HIV progression toward AIDS are limited by multiple issues, including the viral strain variability within the study subjects. In this study, in a cohort of children infected with a monophyletic strain (CRF02_AG) during an outbreak, we evaluated the HIV-1 Gag, Vif, Vpr, Tat and hepatitis C virus E1/E2 (as control) proteins circulating in a cohort for the capability to be presented by the HLA molecules in the same population. A total of 70 Non-progressors and 37 Progressors to AIDS were evaluated.…

MalevirusesHepatitis C virusImmunologyPopulationHIV InfectionsHuman leukocyte antigenBiologymedicine.disease_causeMajor histocompatibility complexgag Gene Products Human Immunodeficiency VirusEpitopeAntigenHLA AntigensT-Lymphocyte SubsetsConsensus SequencemedicineHumansImmunology and AllergyAmino Acid SequenceChildeducationAllelesPhylogenySettore MED/04 - Patologia Generaleeducation.field_of_studyHistocompatibility TestingSettore BIO/12Original ArticlesViral LoadGroup-specific antigenVirologyCD4 Lymphocyte CountPhenotypeChild PreschoolImmunologyDisease ProgressionHIV-1biology.proteinSettore ING-INF/06 - Bioingegneria Elettronica e InformaticaFemaleErratumSequence AlignmentViral load
researchProduct

Weighted Least-Squares Likelihood Ratio Test for Branch Testing in Phylogenies Reconstructed from Distance Measures

2005

A variety of analytical methods is available for branch testing in distance-based phylogenies. However, these methods are rarely used, possibly because the estimation of some of their statistics, especially the covariances, is not always feasible. We show that these difficulties can be overcome if some simplifying assumptions are made, namely distance independence. The weighted least-squares likelihood ratio test (WLS-LRT) we propose is easy to perform, using only the distances and some of their associated variances. If no variances are known, the use of the Felsenstein F-test, also based on weighted least squares, is discussed. Using simulated data and a data set of 43 mammalian mitochondr…

MammalsLikelihood FunctionsModels GeneticReproducibility of ResultsGeneralized least squaresClassificationDNA MitochondrialDistance measuresEvolution MolecularData setData Interpretation StatisticalLikelihood-ratio testStatisticsHIV-1GeneticsAnimalsCluster AnalysisPoint (geometry)PhylogenyEcology Evolution Behavior and SystematicsIndependence (probability theory)Reliability (statistics)Selection (genetic algorithm)MathematicsSystematic Biology
researchProduct

Functional characterization of Tat protein from human immunodeficiency virus. Evidence that Tat links viral RNAs to nuclear matrix.

1990

The processes of transcription and posttranscription are assumed to proceed in close association with the nuclear matrix. In this study we demonstrated that Tat, the trans-activating protein from human immunodeficiency virus type 1 (HIV-1), binds both to the TAR region of the nascent HIV mRNAs and the nuclear matrix with high affinity. Both North/Western blotting experiments and nitrocellulose binding studies revealed that Tat binds with an association constant (K alpha) of approximately 1 x 10(9) M-1 to the TAR segment of HIV RNA; binding of Tat to this sequence which is present between position 32 and 82 downstream from the TATA box was also confirmed by gel retardation assays. Binding of…

Messenger RNAViral matrix proteinTranscription GeneticTATA boxBinding proteinGene Products gagCell BiologyBiologyNuclear matrixBiochemistryMolecular biologyCell LineTranscription (biology)Gene Products tatHIV-1Trans-ActivatorsHumansRNA ViralNuclear Matrixtat Gene Products Human Immunodeficiency VirusCloning MolecularBinding siteMolecular BiologyProtein secondary structure
researchProduct

Cytokine-mediated regulation of monocyte/macrophage cytotoxicity in human immunodeficiency virus-1 infection.

1992

Monocyte/macrophage-mediated tumor cytotoxicity was studied in patients infected with human immunodeficiency virus-1 (HIV-1) at various stages [Center for disease control (CDC) classification] of the disease. using the P-815 tumor cell line as target cells, the results demonstrated reduced monocyte/macrophage cytotoxicity early in HIV-1-related disease (CDCIII, P0.01). This cellular dysfunction sustained during the progression of the disease. Evidence could be presented that neither exogenous application of macrophage-stimulating cytokines (e.g. interferons) nor their endogenous induction in vitro restored monocyte/macrophage cytotoxicity. However, enhanced tumor necrosis factor (TNF)-alpha…

Microbiology (medical)AdultCytotoxicity Immunologicmedicine.medical_treatmentImmunologyHIV InfectionsBiologyVirusMonocytesmedicineTumor Cells CulturedImmunology and AllergyMacrophageHumansProstaglandin E2CytotoxicityCells CulturedTumor Necrosis Factor-alphaMonocyteInterleukinsMacrophagesGeneral MedicineMiddle AgedIn vitroCytokinemedicine.anatomical_structureImmunologyHIV-1CytokinesTumor necrosis factor alphaInterferonsmedicine.drugMedical microbiology and immunology
researchProduct

Recent acquired STD and the use of HAART in the Italian Cohort of Naive for Antiretrovirals (I.Co.N.A): analysis of the incidence of newly acquired h…

2008

Objective: To estimate the incidence of newly acquired syphilis (n-syphilis) and hepatitis B infection (n-hepatitis B) in I.Co.N.A. and to evaluate the impact of HAART, calendar date and risk group. Methods: Cohort study: Incidence was calculated by person-years analyses. Poisson regression was used for the multivariate model. Results: The rate of n-syphilis was 23.4/1,000 PYFU and it increased over time; HIV transmission risk was the most important predictor: men who have sex with men (MSM) had a considerable higher risk (RR 5.92, 95% CI 2.95-12.13 vs IDU/exIDU, p < 0.0001). The rate of n-hepatitis B was 12.2/1,000 PYFU; it declined in recent years and halved per 10 years age. Patients wit…

Microbiology (medical)AdultMalemedicine.medical_specialtyHBsAgHAARTPopulationImmunologySexually Transmitted DiseasesHIV InfectionsLower riskRegression AnalysiMen who have sex with menCohort StudiesAcquired immunodeficiency syndrome (AIDS)Internal medicineAntiretroviral Therapy Highly ActivemedicineHumansHIV InfectionPoisson DistributionSyphilisHomosexuality MaleeducationMultivariate AnalysiSexually Transmitted Diseaseeducation.field_of_studybusiness.industryIncidence (epidemiology)Incidencevirus diseasesHIVGeneral MedicineHepatitis Bmedicine.diseaseHepatitis BInfectious DiseasesSyphiliItalyImmunologyCohortMultivariate AnalysisHIV-1Regression AnalysisFemaleCohort StudiebusinessHumanInfection
researchProduct

Diagnosis of human immunodeficiency virus (HIV) infection: multicenter evaluation of a newly developed anti-HIV 1 and 2 enzyme immunoassay.

1994

A new anti-human immunodeficiency virus type 1 and 2 (anti-HIV 1 and 2) test is described. It uses recombinant p24 and peptides covering gp32, gp41, and gp120 to identify HIV-1 and HIV-2 infections. This test has been shown to be specific (99.5%) and sensitive (99.8%). In this respect, the assay was equal or superior to anti-HIV 1 and 2 tests run as references. The test was able to discriminate sera from patients with HIV infections from those from uninfected individuals with excellence; it also exerted high intra- and interassay precisions. The "modular" concept of the test allows the use of single components (gp32 or gp41) to separate between HIV-2 and HIV-1 infections, respectively.

Microbiology (medical)MaleHIV AntigensHIV InfectionsHIV AntibodiesGp41Sensitivity and SpecificityVirusDiagnosis DifferentialImmunoenzyme TechniquesAcquired immunodeficiency syndrome (AIDS)PregnancyImmunopathologyHIV SeropositivityMedicineHumansSidamedicine.diagnostic_testbiologybusiness.industryvirus diseasesmedicine.diseasebiology.organism_classificationVirologyRecombinant ProteinsHIV AntigensEvaluation Studies as TopicImmunoassayImmunologyHIV-2HIV-1FemaleViral diseasebusinessResearch ArticleJournal of clinical microbiology
researchProduct

Reduction of nevirapine-driven HIV mutations by carbamazepine is modulated by CYP3A activity

2014

Item does not contain fulltext OBJECTIVES: The reduction in mother-to-child transmission of HIV-1 by single-dose nevirapine given at birth onset is achieved at the expense of de novo HIV-1 resistance mutations. In the VITA1 study, single-dose carbamazepine accelerated nevirapine elimination, but the accompanying trend towards fewer de novo HIV-1 mutations was statistically non-significant. METHODS: We investigated if the effect of carbamazepine was confounded by the individual variability in nevirapine metabolism and transport. RESULTS: Nine of 34 (26%) single-dose nevirapine-treated women had one or more nevirapine-associated resistance mutations, compared with 3 of 34 (9%) in the single-d…

Microbiology (medical)NevirapineCYP3AAnti-HIV AgentsHuman immunodeficiency virus (HIV)Mutation MissenseEndogenyHIV InfectionsPharmacologyBiologymedicine.disease_causeChemopreventionPregnancyDrug Resistance ViralmedicineClinical endpointCytochrome P-450 CYP3AHumansPharmacology (medical)NevirapinePharmacologyMutationCYP3A4Cytochrome P-450 CYP3A InducersCarbamazepinelnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Infectious DiseasesCarbamazepineTreatment OutcomeHIV-1Femalemedicine.drug
researchProduct

Characterization of new recombinant forms of HIV-1 from the Comunitat Valenciana (Spain) by phylogenetic incongruence

2019

Recombination is one of the main processes shaping the evolution of HIV-1, with relevant consequences for its epidemiology. In fact, Circulating and Unique Recombinant Forms (CRFs and URFs) cause 23% of current infections. The routine analyses of antiretroviral resistance yield partial pol gene sequences that can be exploited for molecular epidemiology surveillance but also to study viral diversity and to detect potential recombinant samples. Among the pol sequences derived from a large sample dataset from the Comunitat Valenciana (Spain), we identified nine putative recombinant samples. We aimed at fully characterizing these samples and performing a detailed analysis of the corresponding r…

Microbiology (medical)Pol genesHuman immunodeficiency virus (HIV)lcsh:QR1-502Computational biologyBiologymedicine.disease_causephylogenyMicrobiologylcsh:Microbiologylaw.invention03 medical and health scienceslawPhylogeneticsCRFsmedicineCRFSOriginal Research030304 developmental biology0303 health sciencesMolecular epidemiologyPhylogenetic tree030306 microbiologynearly-full genomeURFsrecombinationRecombinant DNAHIV-1Recombination
researchProduct